CL2022003472A1 - Compuesto de ftalazinona, y método de preparación y uso médico de este - Google Patents

Compuesto de ftalazinona, y método de preparación y uso médico de este

Info

Publication number
CL2022003472A1
CL2022003472A1 CL2022003472A CL2022003472A CL2022003472A1 CL 2022003472 A1 CL2022003472 A1 CL 2022003472A1 CL 2022003472 A CL2022003472 A CL 2022003472A CL 2022003472 A CL2022003472 A CL 2022003472A CL 2022003472 A1 CL2022003472 A1 CL 2022003472A1
Authority
CL
Chile
Prior art keywords
preparation
compound
medical use
phthalazinone
phthalazinone compound
Prior art date
Application number
CL2022003472A
Other languages
English (en)
Inventor
Lu Hongfu
Xing Weiqiang
Lv Yongcong
Qi Baojian
Peng Jianbiao
Guo Haibing
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of CL2022003472A1 publication Critical patent/CL2022003472A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulgan un compuesto de ftalazinona y un método de preparación para este y el uso médico de este. En particular, se divulgan un compuesto como se representa mediante la fórmula (I), y una sal farmacodinámicamente aceptable, y el uso del compuesto como un receptor de andrógeno (AR) para degradación.
CL2022003472A 2020-06-12 2022-12-07 Compuesto de ftalazinona, y método de preparación y uso médico de este CL2022003472A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010536221 2020-06-12
CN202011147078 2020-10-23
CN202011261665 2020-11-12
CN202110485680 2021-04-30
CN202110614030 2021-06-02

Publications (1)

Publication Number Publication Date
CL2022003472A1 true CL2022003472A1 (es) 2023-06-02

Family

ID=78846889

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003472A CL2022003472A1 (es) 2020-06-12 2022-12-07 Compuesto de ftalazinona, y método de preparación y uso médico de este

Country Status (16)

Country Link
US (2) US20230131252A1 (es)
EP (1) EP4166550A1 (es)
JP (1) JP2023531390A (es)
KR (1) KR20230024328A (es)
CN (2) CN113801098B (es)
AU (1) AU2021286738A1 (es)
BR (1) BR112022025057A2 (es)
CA (1) CA3186981A1 (es)
CL (1) CL2022003472A1 (es)
CO (1) CO2022017802A2 (es)
CR (1) CR20230007A (es)
IL (1) IL298962A (es)
MX (1) MX2022015562A (es)
PE (1) PE20230610A1 (es)
TW (1) TWI781651B (es)
WO (1) WO2021249534A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
BR112022025057A2 (pt) * 2020-06-12 2023-01-31 Shanghai Jemincare Pharmaceuticals Co Ltd Composto de ftalazinona e método de preparação do mesmo e uso médico do mesmo
KR102474999B1 (ko) * 2021-05-26 2022-12-07 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
US20230295105A1 (en) * 2021-05-26 2023-09-21 Innocure Therapeutics, Inc. Piperidinedione derivatives
WO2023016518A1 (zh) 2021-08-11 2023-02-16 四川海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
WO2024054952A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024054953A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200052995A (ko) 2015-01-20 2020-05-15 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
DK3660004T3 (da) 2016-10-11 2023-05-08 Arvinas Operations Inc Forbindelser og fremgangsmåder til målrettet degradering af androgenreceptor
AU2017363257B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
CA3042297A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
MX2019009046A (es) * 2017-01-31 2019-10-30 Arvinas Operations Inc Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.
CN110194762B (zh) * 2018-02-27 2021-09-10 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途
CN112390852B (zh) 2019-08-14 2022-10-18 上海济煜医药科技有限公司 作为蛋白降解剂的化合物及其制备方法和应用
CN112457366B (zh) 2019-09-06 2024-03-19 江西济民可信集团有限公司 作为蛋白降解剂的并环类化合物及其制备方法和应用
CN112457367B (zh) 2019-09-06 2022-08-23 上海济煜医药科技有限公司 作为蛋白降解剂的连环类化合物及其制备方法和应用
CN112574278A (zh) 2019-09-29 2021-03-30 江西济民可信集团有限公司 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
CN113087704B (zh) 2019-12-23 2023-09-08 上海济煜医药科技有限公司 一种蛋白降解剂化合物的制备方法和应用
CN113582974B (zh) 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
BR112022025057A2 (pt) * 2020-06-12 2023-01-31 Shanghai Jemincare Pharmaceuticals Co Ltd Composto de ftalazinona e método de preparação do mesmo e uso médico do mesmo

Also Published As

Publication number Publication date
PE20230610A1 (es) 2023-04-13
CR20230007A (es) 2023-06-01
US20230242510A1 (en) 2023-08-03
JP2023531390A (ja) 2023-07-24
KR20230024328A (ko) 2023-02-20
MX2022015562A (es) 2023-01-30
BR112022025057A2 (pt) 2023-01-31
CN113801098A (zh) 2021-12-17
WO2021249534A1 (zh) 2021-12-16
TW202146400A (zh) 2021-12-16
EP4166550A1 (en) 2023-04-19
CO2022017802A2 (es) 2023-03-17
US11767312B2 (en) 2023-09-26
CN113801098B (zh) 2023-05-30
CA3186981A1 (en) 2021-12-16
CN116082311A (zh) 2023-05-09
AU2021286738A1 (en) 2023-01-19
US20230131252A1 (en) 2023-04-27
TWI781651B (zh) 2022-10-21
IL298962A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
CO2022017802A2 (es) Compuesto de ftalazinona, y método de preparación y uso médico de este
ECSP20067394A (es) Inhibidores de cinasa dependientes de ciclina
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
CO2022010305A2 (es) Método y aplicación de preparación de compuesto como agente de degradación de proteínas
CO2017000222A2 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CR20160032A (es) Compuestos de pirimidinodiona contra estados cardíacos
NI202000092A (es) Compuestos
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
BR112018006025A2 (pt) composição farmacêutica e aplicação da mesma
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CR20120296A (es) Nuevos compuestos de espiropiperidina
CL2023001369A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
EA202193015A1 (ru) Ингибиторы cdk
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
CO2022004978A2 (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CO6341557A2 (es) Derivados nitrogenados de la pancratistatina
DOP2023000129A (es) DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS
CO2023001407A2 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
BR112021023886A2 (pt) Compostos tetracíclicos como inibidores de cdc7
CY1121459T1 (el) Συνθεση ενωσεων τιακουμικινης